Ablation

Cardiovascular

10 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
CellFX Console	Pulse Biosciences Inc Common Stock (DE) (PLSE)
nPulse Console	Pulse Biosciences Inc Common Stock (DE) (PLSE)
nsPFA Percutaneous Electrode System	Pulse Biosciences Inc Common Stock (DE) (PLSE)
Vybrance Percutaneous Electrode System	Pulse Biosciences Inc Common Stock (DE) (PLSE)

Phase 1(1)

Drug	Company
ADXS-504	Ayala Pharmaceuticals, Inc. (ADXS)

Preclinical(2)

Drug	Company
pfca	Adagio Medical Holdings Inc (ADGM)
vclas ultra	Adagio Medical Holdings Inc (ADGM)

Unknown(3)

Drug	Company
CellFX nsPFA 360° Cardiac Catheter	Pulse Biosciences Inc Common Stock (DE) (PLSE)
TactiFlex® and TactiCath® families of ablation catheters	ABBOTT LABORATORIES (ABT)
Volt® Pulsed Field Ablation System	ABBOTT LABORATORIES (ABT)

BioSniper tracks 10 drugs in development for Ablation across 4 companies.

There are 2 clinical trials targeting Ablation tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.